ZVRA News & Events

Reports Q1 revenue $36.2M, consensus $31.96M. In Q1, the company received $40.5M of the $45M in net proceeds from the sale of the SDX portfolio. "Our results demonstrate the differentiated model we have built to drive growth and profitability while expanding access to high-quality, affordable care through a wide-network PPO," said Clover Health CEO Andrew Toy. "During the first quarter, we delivered strong performance across key metrics, driven by deeper clinical engagement, with Clover Assistant supporting earlier intervention and better outcomes for our members. As we continue to scale our technology to reach more members, we expect to achieve our first full year of GAAP Net Income profitability in 2026."

Zevra Therapeutics announced an agreement under which Commave Therapeutics will purchase Zevra's serdexmethylphenidate portfolio, including AZSTARYS and KP1077, for $50 million. Zevra and Commave had previously entered into a 2019 license agreement under which Zevra granted Commave an exclusive license to certain SDX products. In 2024, Commave initiated litigation in Delaware Chancery Court against Zevra, and as part of today's purchase agreement between the companies, the parties mutually agreed to settle the dispute. Prior to entering into the agreement, the Company repaid the principal balance on its $63 million term loan in full, resulting in a strong, debt-free balance sheet and enhanced financial and strategic flexibility.